XA-1 can simultaneously block both PD-1 and PD-L1 to result in complete blockade of PD-1/PD-L1 pathway and facilitate bridging between the PD-L1 positive tumor cells and PD-1-positive-activated T-cells in tumor microenvironment (TME). This evidence concerns the gene CD274 and neoplasm.